Articles tagged with Liver Cancer
Researchers from Institute of Science Tokyo reveal the SPP1–CD44–Hedgehog signaling pathway as a key driver of fibrosis in liver tumors, hinting at its potential as a therapeutic target. The study provides valuable insights into how liver tumors actively shape their surroundings, driving the onset and progression of fibrosis.
A positive feedback loop between UBE2V1 and HIF-1α drives HCC progression by facilitating tumor growth and metastasis. UBE2V1 promotes HCC progression by competing with HIF-1α for VHL protein binding, leading to sustained HIF-1α stabilization.
Women with cardiometabolic risk factors such as type 2 diabetes and high waist circumference face a higher risk of liver fibrosis, with rates increasing 11-fold and 2.8-fold compared to men. The study highlights the importance of managing these risk factors for liver health beyond heart disease prevention.
Researchers found that quantifiable HBV RNA levels are associated with a significantly higher risk of HCC, independent of traditional risk factors. Chronic hepatitis B patients with concurrent liver dysfunction should be intensified under surveillance for HCC.
A study from The University of Osaka reveals a molecular pathway connecting liver congestion to liver fibrosis, portal hypertension, and liver tumorigenesis. Researchers identified increased activity of YAP and CTGF in liver sinusoidal endothelial cells as key molecules involved in this signaling pathway.
Researchers create detailed 3D reconstructions of human liver tissue, comparing healthy and cirrhotic livers, showing dysregulation of metabolite transport, reduced specialized cells, and disruption of vascular networks. The study highlights the importance of understanding organ structure for bioprinting artificial organs.
A study by RIKEN researchers identifies a MYCN-driven biomarker that predicts the risk of liver cancer. The biomarker, known as the MYCN niche score, uses machine learning to analyze gene expression patterns and indicates whether a tumor-free liver is at high risk for developing tumors.
Researchers at PolyU have identified a key driver of tumour growth in liver cancer and developed a monoclonal antibody that neutralises this protein. The antibody inhibits the growth and proliferation of FABP4-driven cancer stem cells, enhancing immune cell activity.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Researchers uncover a hypoxia–m⁶A–Gal-1 regulatory axis that fuels HCC progression by stabilizing Galectin-1 (Gal-1) mRNA, promoting malignant phenotypes. Functional experiments confirmed Gal-1's role in enhancing HCC cell proliferation, migration, invasion, and EMT-driven phenotypic plasticity.
Ochsner MD Anderson is offering histotripsy, a revolutionary non-invasive treatment for liver tumors, approved by the FDA in 2023. The procedure uses ultrasound energy to destroy liver tumors in a single outpatient procedure.
The American Cancer Society's new 'Cancer Statistics, 2026' report reveals a historic milestone: US cancer survivorship has reached a record 70%, driven by major gains in cancers once considered difficult to treat. However, the report also highlights persistent disparities, concerning increases in cancer among women and younger adults.
Researchers found that blocking Caspase-2 enzyme in mice increased chronic liver damage and cancer risk as they aged. The study highlights the need for caution when targeting this pathway to treat fatty liver disease.
A new rapid test for hepatitis C could identify more patients who can be cured if insurers increase reimbursement to cover the test's high cost. The test's point-of-care feature makes it ideal for early screening and treatment in clinics and emergency rooms.
A new MIT study shows that high-fat diets cause liver cells to revert to an immature state, making them more susceptible to cancer-causing mutations. This reversion is driven by genes that help the cells survive stressful conditions, but ultimately increases their likelihood of becoming cancerous.
UT Health San Antonio received $3 million in CPRIT grants to expand access to preventive salpingectomy, test novel methods to prevent liver cancer, and advance treatment for therapy-resistant metastatic breast cancer. These projects aim to improve cancer prevention, diagnosis, and treatment in South Texas.
Scientists identify targeting B-cells as a promising strategy to improve liver cancer immunotherapy. Researchers found that tumor-associated B-cells suppress T-cell activity, allowing cancer cells to escape immune attacks.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
A national survey of adults found that three-quarters support vaccinating newborns against hepatitis B, but Republicans are less likely to recommend the vaccine. The survey also found that most respondents believe the vaccine protects against liver disease, and there is little evidence justifying delaying vaccination.
A recent study by UCLA Health investigators found that mental health conditions significantly raise the likelihood of developing liver cancer among US veterans living with cirrhosis and hepatitis C. The study suggests that these disorders limit access to hepatitis C care, reducing the chance of a cure.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
A novel liver cancer vaccine has achieved responses in a rare disease affecting children and young adults, with 75% of patients experiencing disease control. Three patients are now believed to be cancer-free after receiving the therapy, including a 13-year-old patient who achieved a nearly complete response.
The institute has opened its first specialized angiography-CT suite, integrating two forms of imaging equipment in one dedicated space. This allows interventional radiologists to perform both angiography and CT scans on the same day, reducing travel burdens for patients and improving treatment outcomes.
A new study in the Journal of Hepatology shows liver transplantation from MAiD donors yields similar survival rates as standard donation after circulatory death. This practice can significantly expand the donor pool, leading to more organs available for transplant and potentially saving thousands of lives.
Researchers identified a significant association between perfluoroheptanoic acid (PFHpA) exposure and metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents. The study used advanced models to reveal PFHpA's role in disrupting biological pathways, leading to liver damage and inflammation.
Glypican-3 is a key driver of hepatocellular carcinoma progression, facilitating metastasis and tumor microenvironment remodeling. Immunotherapy targeting GPC3 has shown preliminary safety and antitumor activity in clinical trials, with ongoing research focusing on optimized patient selection and disease monitoring.
Researchers have discovered myeloid cells in children's liver tumors that could be activated for treatment. This discovery provides new avenues for immunotherapy in childhood liver cancer.
A simple blood analysis can predict the risk of developing severe liver disease, enabling earlier detection and potentially improving treatment outcomes. The CORE model, developed by Karolinska Institutet researchers, is based on three routine blood tests and has been shown to be highly accurate in predicting liver disease risk.
The University of Cincinnati Cancer Center researchers are presenting several studies on radiation oncology, including the evaluation of efficacy and safety of proton re-irradiation in head and neck cancers, significant variation in oropharyngeal cancer treatment approaches, and severe toxicity rare following liver cancer ablative radi...
Researchers have identified CNNM4 as overexpressed in cholangiocarcinoma and found that inhibiting it, combined with GalNAc siRNA technology, can slow tumor growth and increase sensitivity to treatment. This approach could lead to personalized therapies for patients with limited treatment options.
DDX17 promotes HCC metastasis via the β-catenin/TCF4 pathway, inducing EMT and enhancing migration/invasion. The β-catenin/TCF4/DDX17 feedback loop is essential for HCC dissemination.
Researchers found that four common PFAS triggered fat buildup and cancer-related changes, with effects differing by sex. Liver cells from male and female donors responded differently to PFAS exposure.
Researchers have created a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents. This innovative platform replicates the microenvironment of liver tumors, providing unprecedented insight into how tumors respond to embolization.
Researchers at the University of Mississippi have developed a new method to deliver cancer therapies directly to triple-negative breast cancer cells. The sugar-coated nanoparticles effectively target this aggressive cancer, which affects young women and disproportionately impacts Black women. The discovery holds promise for treating no...
A new study found that a cell-based vaccine using dendritic cells can improve progression-free survival time for patients with intermediate-stage primary liver cancer. The ImmunoTACE trial showed an average of 18 months of tumor progression compared to 10 months in the control group.
The Lancet commission emphasizes the need for concrete goals to reduce hepatocellular carcinoma's growing disease burden. The authors propose a 2% annual reduction in age-standardized incidence rates and recommend evidence-based strategies to tackle viral hepatitis, alcohol consumption, environmental risk factors, and disparities in he...
Researchers have discovered a promising new approach to suppress the growth of aggressive cancers by targeting minor splicing, a specialized molecular process. By blocking minor splicing, cancer cells accumulate DNA damage and trigger cell death, while healthy cells remain largely unaffected.
Three in five liver cancer cases can be prevented by reducing viral hepatitis, alcohol consumption, and metabolic dysfunction-associated steatotic liver disease. The Lancet Commission estimates that if countries can reduce liver cancer incidence by 2-5% annually by 2050, it could prevent 9-17 million new cases and save 8-15 million lives.
A recent national study reveals complex patterns of burden and survival trends for digestive system malignancies (DSMTs) in China. Despite progress in reducing mortality from some cancers, the overall impact remains significant, with notable disparities across demographic and geographic lines.
Researchers found Galectin-1, a sugar-binding protein, plays a critical role in helping hepatocellular carcinoma cells resist thermal ablation and thrive after being treated with high heat. Blocking Gal-1 can make thermal ablation more effective and reduce the risk of recurrence.
A new study published in the Journal of Hepatology shows that durvalumab plus GemCis significantly improves overall survival for patients with advanced biliary tract cancer. The three-year follow-up analysis found that over twice as many participants treated with durvalumab plus GemCis remained alive compared to those treated with a pl...
A recent analysis of 16 years of data on Japanese adults reveals a strong association between socioeconomic status and the incidence of five common cancers. Communities with low employment rates or low incomes show higher cancer rates compared to those with higher socioeconomic status.
A unique luminescent probe using terbium has been developed to detect β-glucuronidase, an enzyme that can aid in liver cancer diagnosis. The sensor's sensitivity and accuracy are comparable to conventional methods but at a lower cost, making it suitable for resource-limited settings.
Michael Karin, renowned for his work on chronic inflammation and cancer, will lead the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys. He aims to develop new treatments for metabolic and liver diseases, which affect millions of patients worldwide.
Researchers found that hepatitis B virus worsens liver inflammation, making patients more susceptible to early cancer development caused by environmental carcinogens. Limiting carcinogen exposure or reducing inflammation may mitigate this risk.
This study confirms Lycium barbarum contains multiple components that interact with various targets and pathways to treat liver cancer. The active ingredients have good binding ability, indicating a potential therapeutic effect.
Two Purdue researchers received funding to advance university innovations. Andrew Mesecar aims to develop new treatments for hepatocellular carcinoma using patented enzyme inhibitors. Meanwhile, Pablo Zavattieri is working on a patent-pending system to address saltwater intrusion in the Panama Canal.
Researchers have discovered that TAF2 plays a pivotal role in the growth of liver cancer and can help promote tumor formation. The study's findings suggest that targeting TAF2 could lead to more effective treatments for liver cancer.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
High aflatoxin levels in Ghana's maize and peanuts contribute to the country's high liver cancer rates. Experts call for research to quantify the impact of fungal toxins on the disease.
A new study analyzed trends over time in alcohol-linked cancer mortality across the US, finding nearly double the number of alcohol-related cancer deaths between 1990 and 2021. The burden is highest among men over 55, with liver, colorectal, and esophageal cancers seeing significant increases.
A study investigated immune-related adverse events (irAEs) in Latin American patients with advanced liver cancer treated with atezolizumab and bevacizumab. Most irAEs were mild or moderate and resolved within a month, without impacting overall survival.
A study published in the Journal of Clinical and Translational Hepatology found that oleanolic acid can restore drug sensitivity to sorafenib in sorafenib-resistant hepatocellular carcinoma cells. The compound inhibited cell invasion, migration, and upregulated fabp3 expression, leading to restored sensitivity to sorafenib.
Inhibition of Aurora kinases suppresses liver cancer cell proliferation while inducing phenotypic changes resembling normal liver cells. This dual mechanism suggests a promising new approach for liver cancer therapies.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
A study published in The Lancet Regional Health – Europe found that patients with low household income were more likely to be diagnosed late and receive less effective treatment for liver cancer. This highlights the need for targeted screening in deprived areas to improve early diagnosis and survival rates.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
Hepatocellular carcinoma is the most prevalent form of liver cancer, and liver transplantation offers a curative treatment option for appropriately selected patients. Bridging therapies, such as radiofrequency ablation and transarterial chemoembolization, can improve survival outcomes post-transplant by preventing tumor progression.
A new editorial in Oncotarget discusses how artificial intelligence can improve liver imaging by recognizing when it might be wrong. The approach, called 'uncertainty quantification,' helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look.